Press Releases

Delayed 55s

Fastest customizable press release feed in the world.

Signed out · Sign up for real-time

Updates arrive automatically.

  • Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program
    PR·

    Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program

    Mechelen, Belgium; November 16, 2026; 7.30 AM CET regulated information – Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced the initiation of a new share repurchase program of up to €50 million, following completion of its initial €50 million program announced on June 9, 2026. Under the initial program, completed on October 16, 2026, Lakefront repurchased approximately 1.99 million ordinary shares for a total consideration of €50 million. The repurchased shares are held as treasury shares. The new program will be carried out by Morgan Stanley & Co International PLC, acting as an independent financial intermediary under a discretionary mandate and making its trading de

  • Turning Climate Warnings into Energy Action: Tuya Smart Showcases Its AI Energy Solutions at COP31
    PR·

    Turning Climate Warnings into Energy Action: Tuya Smart Showcases Its AI Energy Solutions at COP31

    ANTALYA, Türkiye, Nov. 16, 2026 /PRNewswire/ -- During the 31st United Nations Climate Change Conference (COP31), Tuya Smart (NYSE:TUYA, HKEX: 2391)), a global AI cloud platform service provider, was invited to participate in the COP31 Blue Zone side event titled "From Early Warning to Action: Global Climate Diplomacy and Cooperation."Organized by the United Nations Institute for Training and Research (UNITAR) and CMA Public Meteorological Service Centre (National Early Warning Release Centre), with support from China Energy News and the Committee on International Cooperation and Liaison, China Energy Research Society (CERS), the event aimed to provide an open platform for international dial

  • HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
    PR·

    HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®

    HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug List ("NRDL") effective on January 1, 2027 will continue to include ELUNATE®, ORPATHYS® and SULANDA®. This update reflects expanded coverage for new indications, renewed agreements for existing indications, as well as continued inclusion under current multi-year agreements. Newly Included and Renewed Indications in the Updated NRDL: ELUNATE® (fruquintinib) is newly included for the tre

  • FF EAI Robotics Ecosystem Inc. (FFR) CEO YT Jia Shares Weekly Updates on Robots Delivery to Central Michigan University, Brain Blocks AI Module, and Industrial Scenario Validation
    PR·

    FF EAI Robotics Ecosystem Inc. (FFR) CEO YT Jia Shares Weekly Updates on Robots Delivery to Central Michigan University, Brain Blocks AI Module, and Industrial Scenario Validation

    FFR has delivered two Aegis Ultra robots to Central Michigan University, the first customer for FFR in Michigan. This marks the first sale and delivery to a university lab in the state and moves the Company beyond K–12 schools into universities and research labs, broadening the customer base of FFR's Education and Research Ecosystem.FFR released its first financial results since completing the acquisition of the robotics business last week and FFAI is scheduled to report its 2026 third quarter financial results on Monday, November 16, 2026.FFR team recently completed a simulation-based validation of a label-based parts-sorting scenario using Faber U, our wheeled mobile manipulator.LOS ANGELE

  • PT Freeport Indonesia Announces Senior Notes Offering
    PR·

    PT Freeport Indonesia Announces Senior Notes Offering

    PT Freeport Indonesia ("PTFI" or the "Company") announced today that it intends to offer one or more series of U.S. Dollar denominated senior notes (the "Notes"), subject to market and other conditions (the "Notes Offering"). PTFI intends to use the net proceeds from the Notes Offering to refinance existing indebtedness and for general corporate purposes. The Notes are expected to be rated "Baa3" by Moody’s and "BBB" by Fitch. Citigroup Global Markets Inc. and J.P. Morgan Securities plc are the joint global coordinators for the Notes Offering. BMO Capital Markets Corp., CIMB Bank Berhad, Labuan Offshore Branch, DBS Bank Ltd., The Hongkong and Shanghai Banking Corporation Limited, Singapor

  • Faraday Future Founder and Global CEO YT Jia Shares Weekly Updates on Robots Delivery to Central Michigan University, Brain Blocks AI Module, and Industrial Scenario Validation
    PR·

    Faraday Future Founder and Global CEO YT Jia Shares Weekly Updates on Robots Delivery to Central Michigan University, Brain Blocks AI Module, and Industrial Scenario Validation

    FFR has delivered two Aegis Ultra robots to Central Michigan University, the first customer for FFR in Michigan. This marks the first sale and delivery to a university lab in the state and moves the Company beyond K–12 schools into universities and research labs, broadening the customer base of FFR’s Education and Research Ecosystem.FFR released its first financial results since completing the acquisition of the robotics business last week and FFAI is scheduled to report its 2026 third quarter financial results on Monday, November 16, 2026.FFR team recently completed a simulation-based validation of a label-based parts-sorting scenario using Faber U, our wheeled mobile manipulator. Faraday Fu

  • Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
    PR·

    Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

    Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that its two core assets are covered by China's 2026 National Reimbursement Drug List (NRDL), providing more patients with greater access to innovative treatment options. Specifically: Lisaftoclax has been included in the 2026 NRDL for the first time for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who ha

  • Mesoblast Showcased at ASX Premier Investor Day Event
    PR·

    Mesoblast Showcased at ASX Premier Investor Day Event

    Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian Securities Exchange (ASX) Investor Day in Melbourne at the session titled "Meet the CEO: Inside Australia’s Listed Companies." The presentation highlighted Mesoblast’s transformation into a commercial-stage biotechnology company, continued growth of Ryoncil® (remestemcel-L-rknd) and the opportunity to leverage the Company’s cellular therapy platform across multiple high-value indications. Mesoblast also outlined its key value-creation priorities, including expansion of RYONCIL

  • IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
    PR·

    IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

    Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhibitor IDE892CDKN2A-deficiency is a common tumor suppressor loss prevalent in ~10-15% of all solid tumors, including ~70% of pancreatic cancerIDE101's preclinical profile, including combination results with inhibitors of PRMT5 and pan-RAS, will be summarized at IDEAYA's London R&D DayIND-enabling studies underway to support an IND filing in H1 2027

  • Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
    PR·

    Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16

    - All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6 months) in the six patients who have reached response assessment - - All six patients who have reached response assessment achieved a RANO objective response as their best overall response, with five patients showing complete responses (83.3%), including a previously reported stable disease, and one patient with a partial response (16.7%) with a 58% decrease in tumor measurements - - Primary endpoints of feasibility and safety: planned Alpha DaRT sources were successfully dep

  • Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
    PR·

    Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026

    Helus Pharma Inc. (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists ("NSAs"), today announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder ("MDD"). Please click here to access the webcast or visit the Events & Presentations page of Helus Pharma’s website. The archived webcast will be available on the Company’s website on the Eve

  • Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
    PR·

    Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026

    Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced it will report third quarter 2026 financial results and provide a business update on the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) on Monday, November 16, 2026. A webcast will be held at 8:00 AM ET on November 16, 2026. Analysts and investors can access the live event through the Events & Presentations page in the Investors section of Lexeo’s website. A replay will be available following the call. About LX2020 LX20

  • Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
    PR·

    Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results

    Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with no serious adverse events reportedPreliminary efficacy results expected near the end of 2026 Closed $5 million private placement with OPKO HealthAppointed antiviral drug development leader Carol

  • Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
    PR·

    Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

    Complete Response Letter Received from FDA for BLA Application Based on HARMONi Study Summit Therapeutics Inc. (NASDAQ:SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. Ivonescimab is a novel PD-1 x VEGF bispecific antibody. "As a cancer survivor, I understand firsthand how important it is for patients

  • BA Investors Who Received Shares of The Boeing Company in Connection to Its Merger with Spirit AeroSystems Can Join Fraud Investigation with SBS Law
    PR·

    BA Investors Who Received Shares of The Boeing Company in Connection to Its Merger with Spirit AeroSystems Can Join Fraud Investigation with SBS Law

    Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Boeing Company ("Boeing" or "the Company") (NYSE: BA) who received shares in connection with its December 2025 merger ("the Merger") with Spirit AeroSystems Holdings, Inc. ("Spirit") (NYSE:SPR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Following the Merger with Spirit, shares of Boeing have declined significantly. If you are a shareholder who suffered a loss, cli

  • Hot Wheels Crowns 2026 Legends Tour Winner Following Global Search Across 19 Countries
    PR·

    Hot Wheels Crowns 2026 Legends Tour Winner Following Global Search Across 19 Countries

    A radically reimagined 1979 Chevrolet El Camino takes the top prize in the 2026 Hot Wheels Legends Tour Presented by Mobil 1 The fan-built car will be transformed into an official 1:64-scale Hot Wheels die-cast sold worldwide Tampa custom-car builder Matt McEntegart brings the global title back to the U.S. for the first time since 2022 Photos of the 2026 Hot Wheels Legends Tour winner and runners-up can be found HERE. Mattel, Inc. (NASDAQ:MAT), a leading global play and family entertainment company and owner of one of the world’s most iconic brand portfolios, today announced the 2026 winner of the Hot Wheels™ Legends Tour presented by Mobil 1, the world’s largest traveling car